CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
LUMICKS is creating z-Movi, a high-throughput platform that screens immune cells for cancer immunotherapy. This innovative tool allows researchers to quickly identify effective immune cells, significantly speeding up the development of new cancer treatments and enhancing patient outcomes.
Cell immunotherapy is a breakthrough treatment that uses immune cells to directly attack tumours.
It is considered the mostexciting development in cancer treatment in years.
When it works, patients with life-threatening cancers live far longer ormay even be cured.
But so far, immunotherapy only works for few types of cancer and few patients, and finding the mosteffective immune cells is still an immense challenge.LUMICKS is developing z-Movi, the first high-throughput platform that screens and s…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Netherlands, Amsterdam
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
